Demonstrates improved enantioselectivity in producing citronellal from citronellol, implying better synthesis routes for pharmaceuticals.
Abstract (R)-citronellal is an important intermediate for aroma compounds and pharmaceuticals. Herein, we engineered the choline oxidase, AcCO6, from Arthrobacter chlorophenolicus, to enhance enantioselective oxidation of citronellol. Through site-directed and combinatorial mutagenesis, a quadruple mutant, AcCO6_M4a (W332V/A89S/W331F/N463E) was obtained, exhibiting 336% of the wild-type activity and a 10.2-fold improvement in enantioselectivity (E = 24.2). Structural analysis and MD simulations revealed that the mutations expanded the binding pocket, promoting favorable interactions with (R)-citronellol and enhancing hydride transfer, while disfavoring the (S)-enantiomer. Consequently, the catalytic efficiency (kcat/KM) for (R)-citronellol was 12.5-fold higher than that for (S)-citronellol. Kinetic resolution of racemic citronellol using AcCO6_M4a achieved approximately 50% conversion, yielding (R)-citronellal (86.7% ee) and (S)-citronellol (97.9% ee) with 39.1% and 42.0% yield, respectively. This work demonstrates the potential of engineered AcCO6 for enantioselective biocatalysis, offering an efficient route to synthesize chiral alcohols and aldehydes as intermediates for fragrances and pharmaceuticals.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: